Auxilius Pharma
Hudson, United States
Series C+
Health & Life Sciences
Non-CEE with local presence
Auxilius Pharma is developing a reformulated extended-release medication for chronic stable angina that incorporates nicorandil as the active ingredient, aimed at effective symptom management with a once-daily dosing schedule. This product is designed to reduce the risk of drug tolerance while utilizing established safety and efficacy data through the 505(b)(2) regulatory pathway.
Founded
2018
Employees
7
Total Raised
$7M
Valuation
$29M
Open Positions (0)
No open positions at the moment